Background: Among the 566 patients with follicular lymphomas (FL) included in the GELF 86 prospective trials from October 1986 to September 1995, 372 with progressive/relapsing disease were analyzed retrospectively to identify prognostic factors at first relapse.
Introduction
Follicular lymphomas (FL) account for 22% of nonHodgkin's lymphomas and are a clearly histologically defined type of malignant lymphoma with a molecular abnormality [1] . Patients with stage III or IV FL represent up to 80% of the patients at initial diagnosis and their disease course is characterized by multiple relapses, despite a high response rate after initial therapy [2] [3] [4] . Median survival varies from 5-10 years according to prognostic factors at diagnosis (histology, age, stage, B symptoms, performance status, tumor burden, lactate dehydrogenase, f32-microglobulin) and response to firstline treatment [5] . For patients with an initial diagnosis of FL, therapeutic options may vary from a watchfulwaiting policy to intensive chemo-radiotherapy [6] [7] [8] .
The efficacy of interferon-oc and, more recently, of anti-CD20 monoclonal antibody have also been demonstrated [9, 10] . Many studies have addressed the problem of initial treatment for patients with FL, but few have specifically examined the characteristics, predictors of survival and results of salvage therapies after relapse [4] . For the younger patients with adverse prognostic factors at relapse, several groups have reported results of highdose therapy (HDT) with autologous stem-cell transplantation (ASCT) [11] [12] [13] . In one study, relapse-free survival after HDT was longer when compared with an historical control group [4] . The role of HDT in salvage therapies of patients with relapsing FL remains unsettled and no results from randomized study are available in this setting. To help clinical decisions, we reviewed the management of first relapse for FL patients included in the prospective GELF 86 multicenter trials conducted by a cooperative group in France and Belgium, the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [14, 15] . The major objective was to determine the impact on freedom from second failure (FF2F) and survival of the treatment (intensive or not) given at relapse. Secondarily, we analyzed prognostic factors for survival at relapse.
Patients and methods

The GELF 86 protocol
The GELF 86 protocol was an open phase III trial initiated on 566 FL patients coming from 40 participating medical centers and included from October 1986 to September 1995. All previously untreated patients were eligible for the study if they had stage III-IV FL confirmed by nodal biopsy [9] . Patients with grade 3 FL were not included in the GELF 86 study.
At study entry, the tumor burden was evaluated and patients were classified in two groups according to the presence (high tumor burden) or not (low tumor burden) of one of the following parameters: nodal or extranodal tumor mass with a diameter over 7 cm; involvement of three nodal sites, each with a diameter over 3 cm; systemic B symptoms; large splenomegaly; serous effusion, local risk of compression and leukemia or blood cytopenia. Patients with a low tumor burden were randomly assigned to 1-3 treatment arms: no treatment until progression, oral prednimustine for 18 months or interferon-a2b for 18 months [14] . Patients with a high tumor burden were randomly assigned to one of two treatment arms: CHVP (cyclophosphamide 600 mg/m 2 , doxorubicin 25 mg/m 2 , teniposide 60 mg/m 2 on day 1 and prednisone 40 mg/m 2 for 5 days) monthly for 6 months then, after response, every 2 months for 12 months; CHVP plus interferon-oc2b [15] .
Patients selection
Five hundred sixty-six FL patients were included in the prospective GELF 86 trial. Thirty-six patients were excluded from the present study: non FL on lymph node after histological review (n = 16), insufficient clinical data or follow-up < 3 years (n = 20). At the end 530 patients were eligible for this study. 372 patients experienced a progression and were analyzed for their characteristics and treatment: 281 patients received a standard regimen for first progression and 91 patients received salvage chemotherapy followed by autologous (n = 83) or allogeneic (n = 8) transplantation. Patients who received high-dose therapy and ASCT (it = 34) or allogeneic transplantation (n -3) for subsequent relapse after first progression were not excluded and were analyzed with patients receiving a standard regimen for the first relapse.
Salvage treatments
According to the GELF 86 protocol, the choice for salvage therapies after progression /relapse was made by each physiscian. In 1986, no recommandation could be given and the choice for salvage therapy depended on several factors: -Time period, the first reports of HDT have been published in 1987. Since that time, further positive reports (mostly in aggressive lymphomas), improvement in the feasibility of the procedure and increase in the number of transplantation units made this approach easier. We studied the number of H DT and ASCT performed during three time periods according to the number of relapse observed. We found a slight increase in the number of ASCT performed after 1990: from 1986 to 1989 17% of relapsing patients received HDTand ASCT verms 28% from 1990 to 1993 and 23% from 1994 to 1997. -Age of the patients, and HDT was only given to patients less than 60 years. On the other hand elderly patients were more often treated by single alkylating agent. -Previous treatment and initial tumor burden, treatment at Polychemotherapy included etoposide-ifosfamide combined with mitoxantrone or cisplatin and cytarabine.
relapse differed for the two groups. Seventy percent of the patients with a low tumor burden received a CHVP or CHOP/ ACVBP regimen at relapse (Table 1) . For those patients with a high tumor burden at diagnosis and who had received first-line CHVP, other chemotherapeutic regimens were prescribed at relapse with a combination of etoposide + ifosfamide + mitoxantrone or cisplatine, cisplatine + high-dose cytarabine (DHAP, ESAP). Availability of new drugs, especially purine analogues. Stage and tumor burden at relapse, 9% of relapsing FL patients received local radiotherapy for stage I-II disease at relapse. Single alkylating agent was mostly given to patients with a low tumor burden at relapse.
Analysis of progression/relapse
Clinical progression was defined as a relapse for patients in complete remission, or the appearance of at least one new lesion or the increased volume of preexisting lesion for patients in partial remission. The date of first progression/relapse was the date of modified treatment for clinical progression. For patients initially not treated, progression was defined at the time of institution of treatment for clinical progression. Restaging and treatment choices at clinical progression were made at the discretion of the treating physician. Among the 530 eligible patients. 372 with confirmed FL (70%) included in the GELF 86 protocol and in first progression'relapse before June 1, 1997 made up our study group and their outcomes were analyzed.
Statistical analysis
The time to progression was calculated from the date of randomization to the date of first progression/relapse. The following parameters were recorded: progression on or off therapy (after the end of the first line treatment), new site or not, site of extranodal disease, number of extranodal sites (excluding bone marrow), high tumor burden according to previously described criteria, histology at relapse, salvage treatment, radiation therapy, total body irradiation (TBI). high-dose therapy with autologous or allogeneic transplantation, stem-cell source, purging or not, chemosensitivity before high-dose therapy and response to salvage therapy. Since it was a retrospective analysis, the role of relapse treatment could not be evaluated on an intent-to-treat basis and only treatments really received by the patients, especially HDTan ASCT, were taken into account.
Response was evaluated at the end of relapse treatment and was defined according to established guidelines [9] , Freedom from second failure (FF2F) was calculated from the date of modified treatment for first progression to death or second progression or date of the last follow-up. Survival was measured from the date of modified treatment for first progression to the last follow-up or death, regardless of the cause. Patients alive at the time of analysis were censored at the stopping date (October 1, 1997) or when it was not reached at the date of the last follow-up. Survival curves were calculated using the Kaplan-Meier method, and differences between them were tested for significance with the log-rank test [16] .
The influence, on survival of the following prognostic factors was analyzed with the log-rank test: age >50 years, > 1 extranodal site at relapse, progression on therapy, high tumor burden at diagnosis or at relapse, initial treatment arm, histological transformation (HT), salvage chemotherapy, HDT with ASCT. All of the factors found to be significant at relapse were included in a multivariate analysis using the Cox proportional hazards model [17] . Multivariate analysis was also performed for FF2F. The results are presented in terms of the relative risk for covariate effects, the standard error for the relative risk and associated P-\a\ue. All statistical analyses were performed using the Statistical Application System software (SAS version 6.12, SAS Institute, Cary, North Carolina).
Results
Patients characteristics
Characteristics of patients at relapse are shown in Table 1 according to their initial tumor burden. The median follow-up for living patients is at 44 months after the date of first progression. The median time to progression was 24 months (range 3-102 months) and 33% of the patients progressed on-treatment. The HT rate was at 24% for the 217 patients who had a second biopsy. A high tumor burden at relapse was noted for 61% of the 264 patients for whom information on tumor burden at relapse was available.
Response to salvage treatments and survival
The objective response after completion of salvage therapy for the first relapse was 63% for all patients. The median FF2F was 20 months (confidence interval (CI): 16.2-22.5 months) and 113 patients (30%) remained alive in second remission at the stopping date.
The five-year probability of survival was 42% with a median survival for relapsing patients of 48 months. After relapse/progression, survival was not influenced by the initial arm of treatment for patients with a low tumor burden but the benefit of interferon-a persisted for patients with a high tumor burden (five-year survival 42% vs. 26%, respectively) (P = 0.09). Among relapsing patients, there was no difference in outcome between those treated with a single alkylating agent and those who received polychemotherapy or purines analogues as salvage therapy.
High-dose therapy with ASCT
Eight patients received HDT and allogeneic stem-cell transplantation for first relapse (among them, seven died), and were excluded from the analysis of ASCT. Eighty-three patients received HDT and ASCT, before HDT, 80% of these patients were considered to have chemosensitive disease. The conditioning regimen included a TBI in 59 patients (71%), with the others receiving chemotherapy (BEAM regimen: BCNU 300 mg/m 2 , etoposide 800 mg/m 2 , aracytine 800 mg/m 2 and melphalan 140 mg/m 2 ). The stem-cell source was the blood for 61 patients (73%) and the bone marrow for the others; the stem-cell grafts were subjected to a CD34+ cell selection in 18 patients (22%). Characteristics of patients according to the treatment given at relapse (standard treatment vs. ASCT) are shown in Table 2 . As expected, the median ages differ between the two groups with patients treated intensively being younger, other clinical characteristics were similar.
Objective response to relapse treatment assessed after HDT was higher in the intensive than in the standard arm (88% vs. 54%, respectively). FF2F and survival were prolonged for patients receiving high-dose therapy with ASCT at first relapse vs. standard therapy (respectively, five-year FF2F at 42% (SE = 6.7%) vs. 16% (SE = 2.5%); five-year survival at 58% (SE = 7.2%) vs. 38% (SE = 3.3%) (median FF2F: 42 months, CI:31-5O months vs. 20 months, CI: 16.3-22.5 months) (P -0.0001); (median survival: not reached vs. 37 months, CI: 34-45 months) (P = 0.0002) (Figures 1 and 2) .
Toxic deaths and secondary myelodysplasia-leukemia
Eleven patients died after the first relapse from treatment-related toxicity (intensive arm, n -5; standard treatment, n -6). We observed 5 myelodysplasias and 2 secondary leukemias among the 372 relapsing patients. The crude incidence was at 5% in the intensive treatment group versus 1% in the standard arm.
Prognostic factors at first relapse/progression
According to univariate analysis, among the factors tested, factors at relapse influencing survival were: HT (five-year survival 15% vs. 45%) (P -0.0001), high tumor burden (five-year survival 38% vs. 58%) (P -0.0009), progression on therapy (five-year survival 24% vs. 52%) (P -0.0001), relapse before three years (five-year survival 38% vs. 60%) (P = 0.003), age >50 years (five-year with survival 32% vs. 56%) (P = 0.0001). The benefit of HDT with ASCT was evaluated as a function of significant prognostic factors (Table 3) . Patients with adverse prognostic factors were found to have improved outcomes with intensive treatment. Multivariate analyses were performed for all relapsing patients (excluding allogeneic transplantation at first relapse) with factors relevant for 90% of the patients (Table 4) . They indicate that HDT with ASCT remains an independent factor for prolonged FF2F and survival. To avoid the bias of age we analyzed only patients <65 years, who could receive HDT based on their age (n = 315), the benefit of ASCT persisted (five-year survival 60% vs. 40%; P = 0.001).
Discussion
FL remains an illness characterized by relapses suggesting that the disease is not eradicated by the treatments currently used. After first progression, it has been stated that the long-term prognosis for FL patients is poor, with a median survival below five years, although relapsed patients can achieve subsequent remission with single agent as well as combination chemotherapy [21] . HT to diffuse large-cell lymphoma is frequent in FL and the crude incidence is controversial but HT is always associated with a poorer prognosis [5] [6] [7] . We confirm previously published results and the adverse prognostic value of HT. The remaining adverse prognostic factors identified at progression were: age > 50 years, hightumor burden at relapse, relapse on therapy and early relapse before 3 years post diagnosis. The present study was retrospective but included all patients who relapsed after the GELF 86 protocol and not only patients who were referred for high-dose therapy. The analysis was designed to eliminate some of the bias in patients recruitment that was found in retrospective studies on highdose therapy with ASCT for lymphoma patients. All patients in our report were included in the prospective GELF 86 trial with the same initial treatment guided by the tumor burden at diagnosis and they were treated during the same period of time. Our results showed that, for FL patients in first relapse, HDT with ASCT is significantly superior to standard chemotherapy with a higher response rate after ASCT and the FF2F and the survival were significantly prolonged. As it is a retrospective, not randomized, study some bias are possible and the number of patients was too small to perform a Table 3 . Five-year probability of survival according to prognostic factors at relapse and to treatment (excluding eight patients treated match patients analysis. The chemosensitivity is higher in the intensive arm with 88% of objective response after salvage treatment, whereas this rate was only of 54% in patients treated with the standard arm. Patients in the intensive arm were in good general condition and younger but the benefit of HDT with ASCT remained when we only considered patient less than 65 years. The choice of standard or intensive treatment was made in each center according to their routine practices. Highdose therapy with ASCT has been performed more frequently for FL since 1990, but the median follow-up for surviving patients was the same for patients treated with standard or intensive treatment (Table 2 ). In this study all patients who effectively received intensive treatment, were censored, and when the intent to treat was intensive most patients had been able to receive it except some patients with HTwho never achieved remission. To avoid all these bias we performed a multivariate analysis and the benefit of HDT with ASCT remains significant on FF2F and on survival with a relative risk of death at 0.6.
The results of intensive treatment with ASCT for several series of patients with advanced FL have been published indicating event free-survival around 50% and survival ranging from 60% to 80% [12, 13, 19, 20] . Intensive treatment has been associated with prolonged duration of remission but, so far, no improvement of survival has been demonstrated after short-term followup [4] . High-dose therapy with ASCT has been associated with more prolonged survival in relapse of aggressive lymphoma patients compared to chemotherapy alone [21, 22] . Only randomized studies could definitively prove the benefit of high-dose therapy with ASCT in patients with relapsing FL. Such a study was proposed few years ago by the EBMT group for low-grade lymphomas (CUP trial), since 1993 only 89 patients fulfilled the criteria for randomization [23] . Results were recently updated with a median follow-up of 18 months, progression-free survival is improved in the intensive arm with no benefit on survival [23] . The role of intensive treatment has been now evaluated as first-line therapy for patients with high-tumor burden FL [24] and randomized trials are now in progress.
From our data, HDT with ASCT appears to be a more appropriate therapy for FL patients with initial high-tumor burden and in first progression/relapse, and those with HT, high-tumor burden at relapse or early progression. The results of recent studies focusing on the influence of allogeneic bone-marrow transplantation in FL patients [25, 26] showed prolonged survival but with a high-rate of transplant-related mortality ranging from 30% to 50%. This alternative should be considered when possible, in the youngest patients with poor prognosticfactors.
In conclusion, HDT with ASCT for chemosensitive FL patients in first relapse was associated with significantly prolonged FF2F and survival. The early toxicity of HDT with ASCT has been limited in recent years by the use of growth factors and peripheral blood cells, and the procedure can be proposed to FL patients < 65 years old in first relapse with an initial high-tumor burden or with poor-prognostic factors at relapse.
